Pakistan will soon get ‘made-in-India’ coronavirus vaccines, sources have said, under the United Global Alliance for Vaccines and Immunization or GAVI, a public-private global health partnership to extend access to immunization in poor countries.
Pakistan’s drug regulator, the Drug administrative body of Pakistan, had approved Oxford-AstraZeneca’s Covid-19 vaccine for emergency use in January this year. This was the primary Covid-19 vaccine to be granted approval.
Additionally, Pakistan had also received a tranche of the 500k doses of the Chinese Sinopharm vaccine in January this year.
The coronavirus pandemic in Pakistan, a country of about 220 million people, is relatively in check. The country has since documented over 595,000 confirmed COVD-19 cases, with near 13,000 deaths.
It was reported that just about seven million doses of AstraZeneca’s vaccine would be available for Pakistani citizens within the first quarter of the year and the rest within the second quarter of 2021.
AstraZeneca’s vaccine has been developed with Oxford University researchers and it’s being employed as a part of a mass immunization program within the UK.
Pakistan’s drug regulator recently approved the vaccine together with the Chinese Sinopharm vaccine for emergency use within the country.
China authorized the employment of its Sinopharm vaccine in early January, and it’s currently in use in several countries, including Bahrain and the United Arab Emirates.
Pakistan, together with China, is additionally conducting a Phase 3 trial of another Chinese anti-coronavirus vaccine from Cansino Biologics, Inc. The trial is sort of complete and Pakistani officials expect the initial results are going to be available soon.
The Pakistani government says it plans to vaccinate a minimum of 70% of the country’s adult population to attain herd immunity over the coming months.